Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Abstract Text:

Naresh V Desireddi,Kimberly A Roehl,Stacy Loeb,Xiaoying Yu,Christopher R Griffin,Shilajit K Kundu,Misop Han,William J Catalona,Naresh V Desireddi,Kimberly A Roehl,Stacy Loeb,Xiaoying Yu,Christopher R Griffin,Shilajit K Kundu,Misop Han,William J Catalona,

OBJECTIVES: Since the initiation of prostate-specific antigen (PSA) screening, the progression-free survival (PFS) rates after radical prostatectomy have markedly improved. However, few studies have evaluated whether PFS has improved for stage and grade-matched patients. Our objective was to examine differences in PFS after radical prostatectomy between the pre-PSA era (before 1992) and the PSA era, controlling for tumor stage and grade. METHODS: From 1983 to 2003, 3456 men underwent radical prostatectomy by one surgeon. The 10-year PFS rates were calculated for each era and stratified by pathologic tumor stage and grade. Kaplan-Meier curves were generated to show biochemical PFS over time. RESULTS: The proportion of patients with pathologically organ-confined disease increased from 64% to 69%, consistent with stage migration. The PFS rate in the PSA era was 87%, 63%, 58%, and 31% versus 71%, 63%, 47%, and 19% in the pre-PSA era for Stage pT2R0, pT3R0, pT2-T3R1, and pT3c/N1 disease, respectively. The PFS rate stratified by Gleason grade in the PSA era was 84%, 63%, and 37% versus 66%, 49%, and 32% in the pre-PSA era for Gleason grade less than 7, 7, and 8 to 10, respectively. The 10-year PFS rate for organ-confined disease improved from 70% in the pre-PSA era to 86% in the PSA era. CONCLUSIONS: Patients treated with radical prostatectomy in the PSA era have improved survival outcomes when controlling for pathologic stage and grade. This is likely attributed to the earlier detection of cancer through PSA screening, better identification of patients amenable to curative therapy, and the effects of lead-time bias.

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Publishing Authors By Initials

NV Desireddi,KA Roehl,S Loeb,X Yu,CR Griffin,SK Kundu,M Han,WJ Catalona,NV Desireddi,KA Roehl,S Loeb,X Yu,CR Griffin,SK Kundu,M Han,WJ Catalona,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Urology

VOLUME: 70

Page Numbers: 950-5

Journal Abbreviation: Urology

ISSN: 1527-9995

DAY: 10

MONTH: Nov

YEAR: 2007

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 366151

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.

AFFILIATION: Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Urology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era Related Publications

• Characteristics of prostate cancer detected by digital rectal examination only.
• Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review.
• Combined Prostate-specific Antigen Density and Biopsy Features to Predict "Clinically Insignificant" Prostate Cancer.
• Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
• Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.
• Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
• Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.
• Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer.
• Open radical retropubic prostatectomy.
• Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
• Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
• Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.
• Under diagnosis and over diagnosis of prostate cancer.
• What to Do with an Abnormal PSA Test.